sphingosine-kinase and Peritoneal-Neoplasms

sphingosine-kinase has been researched along with Peritoneal-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for sphingosine-kinase and Peritoneal-Neoplasms

ArticleYear
SPHK1-induced autophagy in peritoneal mesothelial cell enhances gastric cancer peritoneal dissemination.
    Cancer medicine, 2019, Volume: 8, Issue:4

    Gastric cancer peritoneal dissemination (GCPD) has been recognized as the most common form of metastasis in advanced gastric cancer (GC), and the survival is pessimistic. The injury of mesothelial cells plays an important role in GCPD. However, its molecular mechanism is not entirely clear. Here, we focused on the sphingosine kinase 1 (SPHK1) in human peritoneal mesothelial cells (HPMCs) which regulates HPMCs autophagy in GCPD progression. Initially, we analyzed SPHK1 expression immunohistochemically in 120 GC peritoneal tissues, and found high SPHK1 expression to be significantly associated with LC3B expression and peritoneal recurrence, leading to poor prognosis. Using a coculture system, we observed that GC cells promoted HPMCs autophagy and this process was inhibited by blocking TGF-β1 secreted from GC cells. Autophagic HPMCs induced adhesion and invasion of GC cells. We also confirmed that knockdown of SPHK1 expression in HPMCs inhibited TGF-β1-induced autophagy. In addition, SPHK1-driven autophagy of HPMCs accelerated GC cells occurrence of GCPD in vitro and in vivo. Moreover, we explored the relationship between autophagy and fibrosis in HPMCs, observing that overexpression of SPHK1 induced HPMCs fibrosis, while the inhibition of autophagy weakened HPMCs fibrosis. Taken together, our results provided new insights for understanding the mechanisms of GCPD and established SPHK1 as a novel target for GCPD.

    Topics: Aged; Aged, 80 and over; Animals; Autophagy; Biomarkers; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Immunohistochemistry; Male; Mice; Microtubule-Associated Proteins; Middle Aged; Models, Biological; Peritoneal Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Prognosis; Stomach Neoplasms; Xenograft Model Antitumor Assays

2019
Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis.
    The Journal of surgical research, 2016, Volume: 205, Issue:2

    There are no effective treatments for pancreatic cancer peritoneal carcinomatosis (PC) or cancer dissemination in abdominal cavity. Sphingosine-1-phosphate (S1P), a bioactive lipid mediator produced by sphingosine kinases (SphK1 and SphK2), plays critical roles in cancer progression. We reported that SphK1, but not SphK2, is responsible for S1P export from breast cancer cells and recently discovered that S1P is linked to inflammation and cancer in colitis-associated cancer progression. Given the fact that inflammation is known to be essential for the establishment and progression of PC, we hypothesized that SphK1 in the host animals is involved in progression of pancreatic cancer PC.. Murine pancreatic adenocarcinoma panc02-luc cells were intraperitoneally injected into wildtype or SphK1 knockout (KO) mice to generate a syngeneic PC model. Cell proliferation and apoptosis were determined by Ki67 and TUNEL staining, respectively.. All the animals developed panc02-luc PC. SphK1 KO mice developed significantly less tumor burden, less total tumor weight, and fewer number of PC nodules at 14 d after implantation. Histologically, less inflammatory cell infiltration and less cancer cell proliferation were observed in the tumors. There was no difference in apoptosis.. Our results raise an intriguing possibility that S1P generated by SphK1 in the host promotes pancreatic cancer PC progression by stimulation of proliferation of cancer cells.

    Topics: Adenocarcinoma; Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Transplantation; Pancreatic Neoplasms; Peritoneal Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Tumor Burden

2016